secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042659
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports FY2024 net loss $161.7M; cash $440.5M; pipeline on track for 2025 IND filings
--------------------------------------------------------------------------------

- Net loss for FY2024 $161.7M ($0.69/sh) vs $125.0M ($0.83/sh) in 2023.
- Cash, equivalents & marketable securities $440.5M at Dec 31, 2024, up from $322.0M; runway extended to H2 2027.
- R&D expenses $115.4M (excl. $22.5M in-process R&D) vs $103.8M; G&A $41.7M vs $37.7M.
- IND filings expected mid-Q2 2025 for pan-RAS glue ERAS-0015 and Q2 2025 for pan-KRAS inhibitor ERAS-4001.
- Phase 3 SEACRAFT-2 (naporafenib+trametinib) Stage 1 random data H2 2025; FDA FTD in NRASm melanoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017025042659/0000950170-25-042659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017025042659/eras-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer